Herrmann Ken 4

What Happened

• Ken Herrmann, a director of Aktis Oncology (AKTS), exercised 3,065 stock options and immediately sold the resulting 3,065 shares. He paid $0.08 per share on exercise (total cost $245) and sold the shares in open market transactions at a weighted average price of $25.21, generating gross proceeds of about $77,259. The Form 4 also reports the derivative conversion associated with the exercise.

Key Details

• Transaction date: July 17, 2026.
• Exercise: 3,065 shares acquired at $0.08 per share (total $245).
• Sale: 3,065 shares sold at a weighted average price of $25.21 per share (gross proceeds ≈ $77,259). Reported sale prices ranged from $25.00 to $25.4950 (see footnote F1).
• Derivative reporting: The filing shows the option exercise/conversion (M) and the related derivative disposition (reported at $0.00), reflecting conversion of the option into shares.
• Footnotes: F1 = weighted-average sale price; seller can provide breakdown by price on request. F2 = the options had vested in full.
• Shares owned after transaction: Not disclosed in this filing.
• Filing timeliness: No late filing indicated.

Context

• This appears to be a cashless exercise: the director exercised vested options and sold the shares immediately, a common way to realize gains to cover exercise costs and taxes. Such sales are routine and report proceeds but do not by themselves indicate management’s longer-term view.